TESARO® logo_RGB_small.png
TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
June 03, 2017 18:30 ET | TESARO, Inc.
Initial TOPACIO data for niraparib plus KEYTRUDA® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancerPhase 1 results for TSR-042 show anti-PD-1...
DrHoffman
AntiCancer PDOX Reaches Series A Financing Target, Appoints Board
June 01, 2017 16:24 ET | AntiCancer PDOX, Inc.
CHICAGO, June 01, 2017 (GLOBE NEWSWIRE) -- ASCO 2017 -- AntiCancer PDOX, Inc. announced today that it has reached its original Series A financing target and appointed its Board of...
ASCO 2017 300x250-01 (1) (004)
Crown Bioscience Showcases Dramatic Proficiency in PDX Models and Emerging Expertise in Immune-Oncology
June 01, 2017 04:57 ET | Crown Bioscience
SANTA CLARA, Calif., June 01, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE: ticker 6554) and a global drug discovery and development...
Axiom-22 Anniversary Logo - Transparent.png
Axiom Real-Time Metrics Showcasing Fusion eClinical Suite at the 2017 ASCO Annual Meeting in Chicago
May 30, 2017 14:04 ET | Axiom Real-Time Metrics Inc.
TORONTO, ON--(Marketwired - May 30, 2017) - Axiom Real-Time Metrics, the premier provider of eClinical software solutions and services to small to mid-sized life sciences organizations, will be...
TESARO® logo_RGB_small.png
Tesaro Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2017 16:15 ET | TESARO, Inc.
Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical...
Leap Therapeutics Pr
Leap Therapeutics Presents Positive DKN-01 Clinical Data in Biliary Tract Cancers at American Society of Clinical Oncology (ASCO) 2017 Annual Meeting
May 17, 2017 17:16 ET | Leap Therapeutics
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported interim data...
jounce.png
Jounce Therapeutics to Present Phase 1 Data from JTX-2011 ICONIC Trial at 2017 American Society of Clinical Oncology Annual Meeting
May 17, 2017 17:00 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 17, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
jounce.png
Jounce Therapeutics Initiates Phase 2 Portion of ICONIC Study of JTX-2011 in Patients with Advanced Solid Tumors
April 20, 2017 16:01 ET | Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 20, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
VB-111 Clinical Data
VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer
June 06, 2016 07:00 ET | VBL Therapeutics
VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose level (810 days vs. 172 days, p=0.042)60% (9 of 15) durable response rate (as measured by...
Adaptimmune logo Colour_white background_no strap.jpg
Adaptimmune Announces Data from Clinical Studies of NY-ESO-1 SPEAR™ T-Cells in Multiple Cancers at the 2016 Annual American Society of Clinical Oncology (ASCO) Meeting
June 05, 2016 09:05 ET | Adaptimmune Therapeutics plc
PHILADELPHIA and OXFORD, United Kingdom, June 05, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced a poster...